Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [MON_RNAseq]

ABSTRACT: Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [MON_RNAseq]

PROVIDER: PRJNA1292874 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Similar Datasets

Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy

Project description:Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy

| PRJNA1292875 | ENA

Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy

Project description:Initial surgery and platinum-based chemotherapy is extensively applied to ovarian cancer. Although the majority of patients were sensitive, most relapse at later stage, highlighting the urgent need to understand the tumor microenvironment in ovarian cancer following NACT (neoadjuvant chemotherapy). Through analyzing the published scRNA-seq on human high-grade serous ovarian cancer and performing several in vitro and in vivo experiments, we found prostaglandins-mediated immunosuppressive microenvironment formation is a critical contributor to chemotherapy-resistant upon cisplatin treatment. In mechanisms, cisplatin-treated ovarian cancer cells induce the formation of MDSCs, which passivates the cytotoxicity of CD8+T cell. Moreover, we also carried out scRNA-seq on mice ovarian cancer intraperitoneal injection model to confirm our findings. Notably, Collaborative application of cisplatin and prostaglandins-specific inhibition boosts the cytotoxicity of CD8+T cell and greatly improves the effective rate compared to cisplatin monotherapy.

2025-07-24 | GSE302947 | GEO

Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [MON_RNAseq]

2025-07-24 | GSE302946 | GEO

Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [scRNA-seq]

2025-07-30 | GSE303696 | GEO

Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [scRNA-seq]

Project description:Dynamic change of immune microenvironment in ovarian cancer following neoadjuvant chemotherapy [scRNA-seq]

| PRJNA1297110 | ENA

Improved T cell immunity following neoadjuvant chemotherapy in ovarian cancer

Project description:To investigate effects of standard-of-care neoadjuvant carboplatin and paclitaxel chemotherapy on T cell immunity, we surveyed changes in the peripheral T cell receptor repertoire. We performed bulk TCR sequencing of peripheral blood before chemotherapy (baseline), after 3 cycles (C3) and after 6 cycles (C6).

2022-06-22 | GSE206339 | GEO

TMT-based Quantitative Proteomics Identifies Protein Markers of Resistance to Neoadjuvant Chemotherapy in Ovarian Cancer

Project description:The high rate of recurrence and chemoresistance necessitates in ovarian cancer warrants further research into tumor markers characterizing the resistant population. The proportion of drug-resistant tissue cells in residual lesions after neoadjuvant chemotherapy increases, and drug-resistant markers are enriched. However, there is a lack of comprehensive understanding of tumor marker predoninance pre- and post- neoadjuvant chemotherapy. Here we performed quantitative proteomic analysis of TMT in three patients with matched pretreatment biopsies and post-NACT ovarian cancer tissues. This study highlights a dominant molecular subpopulation that persists in the ovary after neoadjuvant chemotherapy exposure in order to elucidate how it is involved in mediating chemotherapy response, which will lay the foundation for the development.

2023-08-01 | PXD044243 |

Project description:We explore the potential of immune-associated expression profiles in a series of Epithelial Ovarian Cancer (EOC) patients undergoing neoadjuvant chemotherapy (NACT), comparing primary lesions before patients underwent carboplatin/paclitaxel-based NACT (so-called ´biopsy samples´) and interval debulking surgery (IDS) samples from residual lesions after treatment with chemotherapy (so-called ´surgery samples´).

2022-01-27 | GSE181597 | GEO

Proteomic Alterations Associated with Residual Disease in Neoadjuvant Chemotherapy Treated Ovarian Cancer Tissues

Project description:Optimal cytoreduction to no residual disease (R0) correlates with improved disease outcome in the management of high-grade serous ovarian cancer (HGSOC) patients. Neoadjuvant chemotherapy (NACT) followed by interval debulking surgery (IDS) offers an alternate approach to management of HGSOC patients to achieve complete resection. This study assessed proteomic alterations in matched, chemotherapy naïve and NACT-treated patients tumors obtained from HGSOC patients with suboptimal (R1) versus optimal (R0) debulking at IDS. We describe distinct proteome profiles in pre- and post-NACT HGSOC tumors correlating with residual disease status providing prognostic biomarkers for residual disease at IDS as well as candidate proteins associated with NACT resistance warranting further pre-clinical investigation.

2022-10-05 | PXD031929 | Pride

Neoadjuvant chemotherapy modulates T cell responses in high-grade serous ovarian cancer metastases

Project description:Our data suggest that neoadjuvant chemotherapy enhances anti-cancer responses of T cells in peritoneal metastases of patients with high-grade serous ovarian cancer but does not decrease levels of immune checkpoint molecules, providing a rationale for sequential chemo-immunotherapy.

2016-07-27 | GSE71340 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data